CITIUS PHARMACEUTICALS INC (CTXR)
US17322U2078 - Common Stock
| MRQ (2023-12-31) | 2023 (2023-9-30) | 2022 (2022-9-30) | 2021 (2021-9-30) | 2020 (2020-9-30) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 20.35M | 26.48M | 41.70M | 70.10M | 13.90M | |||
| Receivables | N/A | N/A | N/A | N/A | N/A | |||
| Other Current Assets | 7.86M | 7.89M | 2.90M | 2.70M | 100.00K | |||
| Total Current Assets | 28.21M | 34.37M | 44.60M | 72.80M | 14.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 404.85K | 455.86K | 700.00K | 800.00K | 1.00M | |||
| Goodwill | 9.35M | 9.35M | 9.30M | 9.30M | 9.30M | |||
| Intangibles | 59.40M | 59.40M | 59.40M | 59.40M | 19.40M | |||
| Other Non-Current Assets | 38.06K | 38.06K | 0.00 | 0.00 | 100.00K | |||
| Total Non-Current Assets | 69.19M | 69.24M | 69.40M | 69.60M | 29.80M | |||
| TOTAL ASSETS | 97.40M | 103.61M | 114.00M | 142.40M | 43.80M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | |||
| Accrued Expenses | 2.93M | 2.85M | 3.40M | 2.70M | 2.10M | |||
| Accounts Payable | 2.65M | 2.93M | 1.20M | 1.30M | 1.90M | |||
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 5.58M | 5.78M | 4.50M | 4.00M | 4.10M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 200.00K | |||
| Deferred Taxes/Income | 6.28M | 6.14M | 5.60M | 5.00M | 5.00M | |||
| Other Non-Current Liabilities | 204.57K | 262.87K | 500.00K | 700.00K | 900.00K | |||
| Total Non-Current Liabilities | 7.09M | 7.00M | 6.70M | 6.20M | 6.00M | |||
| TOTAL LIABILITIES | 12.67M | 12.78M | 11.20M | 10.20M | 10.10M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -171.46M | -162.23M | -129.70M | -96.00M | -70.60M | |||
| Additional Paid In Capital | 256.04M | 252.90M | 232.40M | 228.10M | 104.20M | |||
| Minority Interest | 600.38K | 600.38K | 600.00K | 600.00K | N/A | |||
| Common Shares | 158.97K | 158.86K | 100.00K | 100.00K | 100.00K | |||
| Shares Outstanding | 158.97M | 158.86M | 146.20M | 146.00M | 55.60M | |||
| Tangible Book Value per Share | 0.10 | 0.14 | 0.23 | 0.43 | 0.09 | |||
| Total Shareholders' Equity | 84.73M | 90.83M | 102.80M | 132.20M | 33.70M | |||
| TOTAL LIABILITIES AND EQUITY | 97.40M | 103.61M | 114.00M | 142.40M | 43.80M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.01 | |||
| Current Ratio | 5.06 | 5.95 | 9.91 | 18.20 | 3.41 | |||
| Return On Assets (ROA) | -40.39% | -32.52% | -29.51% | -17.21% | -40.07% | |||
| Return On Equity (ROE) | -46.42% | -37.10% | -32.72% | -18.54% | -52.08% | |||
All data in USD